Please ensure Javascript is enabled for purposes of website accessibility

Why Bionano Genomics Stock Soared Today

By Joe Tenebruso - Jun 7, 2021 at 5:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The genetic testing specialist is bolstering its leadership ranks.

What happened 

Shares of Bionano Genomics (BNGO 5.81%) surged 22% on Monday after the genome analysis company announced the hiring of a new chief commercial officer. 

So what

Jason Priar will head up Bionano's sales teams and spearhead its revenue growth initiatives. He will be charged with striking deals with insurance companies and other third-party payers.

Priar previously served in healthcare-related sales and leadership positions at businesses including Forest Laboratories, PerkinElmer Genomics, and genetic testing specialist GeneDx. Notably, Priar helped GeneDx's sales rise from $8 million to more than $225 million during his time at the company.

A person is pointing to an upwardly sloping line labeled sales.

Investors hope Bionano Genomics' new CCO will help to turbocharge its revenue growth. Image source: Getty Images.

"Jason's intimate familiarity with the needs of traditional cytogenomics laboratories performing genome analysis in cancer and genetic diseases, combined with his understanding of needs of the physicians and pharmaceutical partners who apply the data, is among the best I have encountered in the industry," Bionano CEO Erik Holmlin said in a press release. "I believe adding Jason to an already stellar team can have a profound impact on Bionano."

Now what

Mentions regarding Bionano have ramped up on Reddit's investing forums in recent days. Some traders appear to be attempting to create a short squeeze in the biotech's shares. This sharp increase in bullish chatter on social media sites likely also contributed to Bionano's gains on Monday. 

Yet Bionano is more than just a meme stock. Its Saphyr genome mapping system is earning strong reviews from healthcare researchers. Analysts, in turn, see plenty of upside for its shares. The consensus estimate calls for Bionano's stock to reach $12 in the next year -- or about 43% above its closing price on Monday.


Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bionano Genomics, Inc. Stock Quote
Bionano Genomics, Inc.
$2.55 (5.81%) $0.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.